Delivery of the Brainshuttle™ amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans,mAbs

当前位置： X-MOL 学术 › mAbs › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Delivery of the Brainshuttle™ amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans
mAbs ( IF 5.3 ) Pub Date : 2023-10-12 , DOI: 10.1080/19420862.2023.2261509
Hans Peter Grimm ₁ , Vanessa Schumacher ₁ , Martin Schäfer ₂ , Sabine Imhof-Jung ₂ , Per-Ola Freskgård ₁ , Kevin Brady ₁ , Carsten Hofmann ₁ , Petra Rüger ₂ , Tilman Schlothauer ₂ , Ulrich Göpfert ₂ , Maximilian Hartl ₂ , Sylvia Rottach ₂ , Adrian Zwick ₂ , Shanon Seger ₁ , Rachel Neff ₁ , Jens Niewoehner ₂ , Niels Janssen ₁

Affiliation

There are few treatments that slow neurodegeneration in Alzheimer’s disease (AD), and while therapeutic antibodies are being investigated in clinical trials for AD treatment, their access to the ce...

中文翻译：